Treats C. difficile -associated diarrhea. ANDA 220465, held by Sandoz. Fidaxomicin.
As of Nov 16, 2026, ANDA 220465 (Fidaxomicin), held by Sandoz, was first approved by FDA on Aug 13, 2026, with 0 approved supplements and 0 published complete response letters.
Fidaxomicin tablets are a macrolide antibacterial indicated in adult patients for the treatment of C. difficile -associated diarrhea. To reduce the development of drug-resistant bacteria and maintain the effectiveness of fidaxomicin tablets and other antibacterial drugs, fidaxomicin tablets should be used only to treat infections that are proven or strongly suspected to be caused by C. difficile. 1.1 Clostridioides difficile -Associated Diarrhea
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 13, 2026 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Fidaxomicin200MG · tablet;oral | Fidaxomicin | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters